Correlation of cytokine levels and response to radiation therapy and/or brachytherapy in low/intermediate risk prostate cancer.

被引：0
|
作者：
Ashamalla, H
Marella, V
Feliberti, J
Kavosh, E
Guirguis, A
Fahim, O
Wise, G
机构：
[1] NY Methodist Hosp, Brooklyn, NY USA
[2] Maimonides Hosp, Brooklyn, NY 11219 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：190S / 190S
页数：1
相关论文
共 50 条
  • [1] Treatment results of brachytherapy versus external beam radiation therapy for intermediate risk prostate cancer.
    Goy, Barry W.
    Soper, Margaret S.
    Chang, Tangel
    Cosmatos, Harry A.
    Slezak, Jeff M.
    Tome, Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [2] Combined Low Dose Rate Brachytherapy and External Beam Radiation Therapy for Intermediate-Risk Prostate Cancer
    Chao, Michael
    Joon, Daryl Lim
    Khoo, Vincent
    Spencer, Sandra
    Ho, Huong
    Guerrieri, Mario
    Foroudi, Farshad
    Bolton, Damien
    JOURNAL OF MEDICAL IMAGING AND RADIATION SCIENCES, 2019, 50 (01) : 82 - 86
  • [3] Determinants of the combined use of external beam radiation therapy and brachytherapy for low-risk localized prostate cancer.
    Quek, Ruben G. W.
    Master, Viraj A.
    Ward, Kevin C.
    Lin, Chun Chieh
    Virgo, Katherine S.
    Portier, Kenneth M.
    Lipscomb, Joseph
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [4] Hormonal Therapy or External Beam Radiation with Brachytherapy and the Risk of Death from Prostate Cancer in Men with Intermediate Risk Prostate Cancer
    Rosenberg, J. E.
    Chen, M.
    Nguyen, P. L.
    Braccioforte, M. H.
    Moran, B. J.
    D'Amico, A. V.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 78 (03): : S367 - S368
  • [5] Management of isolated local failures following stereotactic body radiation therapy for low to intermediate risk prostate cancer.
    Drescher, Nicolette
    Aghdam, Nima
    Danner, Malika
    Ayoob, Marilyn
    Yung, Thomas M.
    Lei, Siyuan
    Collins, Brian Timothy
    Lischalk, Jonathan
    Dritschilo, Anatoly
    Suy, Simeng
    Kumar, Deepak
    Lynch, John J.
    Collins, Sean P.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [6] HDR brachytherapy as monotherapy for low and intermediate risk prostate cancer
    Gaudet, M.
    Pharand-Charbonneau, M.
    Wright, D.
    Desrosiers, M.
    Haddad, A.
    RADIOTHERAPY AND ONCOLOGY, 2019, 133 : S1188 - S1188
  • [7] Intermediate-risk profile in prostate cancer. Role of combined radiation and hormone therapy
    Beck, Marcus
    Boehmer, Dirk
    Hoecht, Stefan
    Zschaeck, Sebastian
    Budach, Volker
    Wiegel, Thomas
    Ghadjar, Pirus
    ONKOLOGE, 2019, 25 (04): : 322 - 329
  • [8] Phase II study of enzalutamide monotherapy with radiation therapy for intermediate risk prostate cancer.
    Bubley, Glenn
    Kaplan, Irving D.
    Werner, Lillian
    Bhatt, Rupal Satish
    Taplin, Mary Ellen
    Mahoney, Kathleen Margaret
    Nguyen, Paul
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [9] TESTOSTERONE THERAPY AFTER RADIATION THERAPY FOR LOW, INTERMEDIATE, AND HIGH RISK PROSTATE CANCER
    Pastuszak, A. W.
    Khanna, A.
    Badhiwala, N.
    Morgentaler, A.
    Hulth, M.
    Conners, W. P.
    Sarosdy, M.
    Carrion, R.
    Lipshultz, L., I
    Khera, M.
    JOURNAL OF SEXUAL MEDICINE, 2015, 12 : 119 - 119
  • [10] Testosterone Therapy after Radiation Therapy for Low, Intermediate and High Risk Prostate Cancer
    Pastuszak, Alexander W.
    Khanna, Abhinav
    Badhiwala, Niraj
    Morgentaler, Abraham
    Hult, Mariam
    Conners, William P.
    Sarosdy, Michael F.
    Yang, Christopher
    Carrion, Rafael
    Lipshultzk, Larry I.
    Khera, Mohit
    JOURNAL OF UROLOGY, 2015, 194 (05): : 1271 - 1276
12345